VIDEO: PSA-targeted lutetium therapy focus of study at ASCO

In this video, Matthew Zibelman, MD, associate professor at the department of hematology/oncology at Temple University Fox Chase Cancer Center, discusses some of the more consequential studies on prostate cancer at ASCO Annual Meeting.

Zibelman discusses studies on PSMA-targeted therapies, along with updates from the TheraP trial and VISION trials, which he says will help decide which patients receive the FDA-approved PSA-targeted lutetium therapy rather than cabazitaxel.

“For prostate cancer, this will be an exciting meeting and really help us make some decisions on how we manage our patients,” Zibelman said.

References:

• Hofman M, et al. TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
• Chi K, et al. ASCO GU 2022: Exposure-adjusted safety analyses of the VISION phase 3 trial of 177Lu-PSMA-617 in patients with mCRPC. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.